Age-related macular degeneration Medical Services in China

Age-related macular degeneration (AMD) is a progressive, chronic eye disease affecting the macula—the central part of the retina responsible for sharp, detailed vision. It primarily occurs in individuals over 50 and is the leading cause of irreversible central vision loss in older adults worldwide. AMD manifests in two forms: dry (atrophic), accounting for ~90% of cases and characterized by drusen accumulation and gradual photoreceptor degeneration; and wet (neovascular), involving abnormal blood vessel growth, leakage, and rapid vision deterioration if untreated. Risk factors include age, genetics (e.g., CFH and ARMS2 variants), smoking, cardiovascular disease, and diet. Early detection via optical coherence tomography (OCT), fundus autofluorescence, and fluorescein angiography is critical. While no cure exists for dry AMD, antioxidant supplementation (AREDS2 formula) may slow progression; wet AMD is effectively managed with intravitreal anti-VEGF injections (e.g., ranibizumab, aflibercept, conbercept), photodynamic therapy, or newer sustained-release implants.

China offers compelling advantages for AMD treatment: world-class ophthalmology centers—such as Zhongshan Ophthalmic Center (Sun Yat-sen University) and Beijing Tongren Hospital—combine cutting-edge imaging, standardized anti-VEGF protocols, and cost-effective care (up to 40–60% lower than Western countries). Chinese clinicians have pioneered innovations like conbercept—a domestically developed anti-VEGF agent approved by NMPA and WHO prequalified—and demonstrated non-inferior efficacy to ranibizumab in large-scale RCTs (e.g., PHOENIX study). Over 2 million AMD patients have received treatment annually in China, with >92% achieving stable or improved visual acuity after one year of regimen adherence.

Treatment Options & Itemized Cost Breakdown: Age-Related Macular Degeneration (AMD)

Non-Surgical / Conservative / Medication Options

*Target criteria:* Early to intermediate dry AMD; stable wet AMD post-treatment; patients ineligible for injections.

• •Nutritional supplementation (AREDS2 formula)

- *Tier 2 (Imported branded, e.g., PreserVision):* ¥280–¥420/month → $40–$60

• •Comprehensive baseline ophthalmic evaluation (visual acuity, Amsler grid, fundus photography, OCT)

• •Annual monitoring package (OCT + fundus autofluorescence + visual field)

Surgical / Procedural / Interventional Options

*Eligibility criteria:* Active neovascular (wet) AMD with subretinal/intraretinal fluid on OCT and/or leakage on fluorescein angiography.

• •Intravitreal anti-VEGF injection (ranibizumab, conbercept, or aflibercept)

- Ranibizumab (Lucentis®): ¥5,200–¥6,800 → $735–$960 - Conbercept (Lampalizumab®): ¥3,600–¥4,900 → $508–$692 - Aflibercept (Eylea®): ¥6,100–¥7,400 → $862–$1,045 - *Typical loading phase (3 monthly injections):* $2,190–$3,135

• •Preoperative workup (mandatory before first injection):

- ¥1,280–¥1,850 → $181–$261

Special / Complex Condition Options

• •Refractory wet AMD (≥3 injections with persistent fluid):

• •Geographic atrophy (advanced dry AMD):

• •Combined AMD + cataract:

Quick Selection Guide

• •Patients <65 years, moderate budget, active wet AMD: Start with conbercept ($508–$692/inj); total 1st-year cost ≈ $3,200–$4,500.
• •Patients ≥75 years, limited mobility/comorbidities (e.g., CHF, CKD): Prioritize AREDS2 supplementation + annual monitoring ($137/year baseline + $92–$130/year follow-up); avoids procedural risk.
• •High-income patients with refractory disease: Pegcetacoplan ($1,780–$2,010/inj × q3mo) — effective for geographic atrophy progression.
• •Severe vision loss (<20/200) + cataract: Combined surgery + anti-VEGF ($2,615–$3,440) delivers dual functional benefit with single anesthesia event.